Detailed Narrative
Strategic Execution and Precision Care
GE HealthCare is two years into its journey as an independent company, demonstrating strong execution on its precision care strategy. This involves evolving from an imaging company to a healthcare solutions provider by offering a comprehensive and integrated portfolio of AI-powered equipment, proprietary radiopharmaceuticals, and digital services. The company's commercial strategy focuses on securing highly strategic, long-term enterprise deals, with 50 closed globally in 2024, totaling over $5 billion in value to date.
Innovation and New Product Introductions (NPIs)
The company introduced approximately 40 innovations in 2024, with products launched within the last three years contributing to a strong new product introduction vitality of approximately 50% for the year. These high-margin NPIs, such as the Allia IGS Pulse cath lab, are outperforming expectations and are expected to drive recurring revenue. GE HealthCare has also expanded its AI leadership, increasing FDA-enabled AI authorizations from 58 to 85 in one year, and upgrading approximately 30% of its MR base with Air Recon DL.
China Market Dynamics and Tariffs
The China market is beginning to show slight improvement in orders growth, aligning with previous commentary. However, the company anticipates negative sales performance in the first half of 2025, leading to a low single-digit decline for the full year, with sequential improvement in the second half. The 2025 guidance also incorporates the impact of new U.S. tariffs on products from China, which are expected to impact adjusted EBIT by approximately 10 basis points and adjusted EPS by about 1 point.
Margin Expansion and Productivity Initiatives
GE HealthCare delivered robust margin expansion, with Q4 adjusted EBIT margin up 260 basis points year-over-year and full-year adjusted EBIT margin expanding 120 basis points. This was driven by productivity improvements, including partnering with suppliers on material costs, design changes, and factory/service productivity, as well as benefits from higher-margin new products. The company's lean culture and operational improvements are expected to continue driving margin expansion into the future.
Capital Allocation and M&A Strategy
The company strengthened its balance sheet by paying down $400 million of debt in 2024 and an additional $250 million in Q1 2025. Strategic tuck-in M&A remains a key focus, complementing existing technologies and solutions. Acquisitions in 2024 included MIM Software (AI-enabled image analysis) and Intelligent Ultrasound (real-time recognition technology). The planned acquisition of NMP aims to deepen radiopharmaceutical distribution capabilities in Japan and other Asian markets, aligning with the strategy to expand beyond imaging.
Flyrcado Launch Preparations
The company is on track to launch its proprietary radiopharmaceutical, Flyrcado, with first dosing expected in Q1 2025 and launch beginning of April. Preparations include sales force expansion, reimbursement efforts, and manufacturing scale-up through partnerships with contract manufacturing organizations (CMOs) located near target geographical areas. The launch will initially target centers with existing cardiovascular PET capabilities, with an estimated revenue contribution of approximately $30 million for FY25.